J&J’s neu­ro­science re­nais­sance? Janssen R&D chief ready­ing for 'gold­en age'

J&J’s Janssen neu­ro­science di­vi­sion has been a sol­id rev­enue con­trib­u­tor fo­cused most­ly on psy­chi­atric drugs — but now its port­fo­lio is head­ed for a change.

Bill Mar­tin, Janssen’s glob­al head of neu­ro­science for re­search and de­vel­op­ment now for 18 months, is look­ing to build out pre­ci­sion prod­ucts as neu­ro­science “en­ters a gold­en age.”

The phar­ma is now “ex­pand­ing our com­mer­cial port­fo­lio be­yond psy­chi­a­try and in­tro­duc­ing new ther­a­pies across neu­ro­log­i­cal neu­rode­gen­er­a­tive and au­toan­ti­body dri­ven dis­eases,” he said in an in­ter­view with End­points Mar­ket­ingRx.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER